Modalis Therapeutics
Modalis is an emerging biotech company that develops therapeutics using CRISPR based technology
Modalis is an emerging biotech company that develops therapeutics using CRISPR based technology
Modalis Therapeutics is a biotech company focused on developing therapeutics using CRISPR-based technology. Founded in 2016 and headquartered in Tokyo, with R&D facilities in Cambridge, it specializes in precision genetic medicines through epigenetic gene modulation. The company's proprietary CRISPR-GNDM technology allows for locus-specific gene expression or histone modification without the need for double-stranded DNA cleavage, gene editing, or base editing.
Modalis is dedicated to advancing therapies for orphan genetic diseases, operating within the Biotechnology and Health Care industries. Notably, their recent achievement includes a $25.00M Series B investment on 10 April 2019, with prominent investors such as SMBC Venture Capital, Mizuho Capital, Pegasus Tech Ventures, UTokyo Innovation Platform, SBI Investment, Shinsei Capital Partners, Fast Track Initiative, Inc., CareNet, and Akira Katayama.
This recent funding is a testament to the promising potential of Modalis Therapeutics and its innovative approach to treating genetic diseases. As a leading player in the biotech space, Modalis is well-positioned to make significant contributions to the field of genetic medicine and CRISPR-based therapies.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $25.00M | 9 |
|
10 Apr 2019 |
| Series A | ¥520.00M | 1 |
|
20 Dec 2017 |
| Series A | ¥900.00M | - | 06 Oct 2017 | |
| Seed Round | ¥60.00M | - | 02 Dec 2016 | |
| Seed Round | ¥50.00M | - | 17 Feb 2016 |
No recent news or press coverage available for Modalis Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
